RANCHO CUCAMONGA, Calif., May 04, 2017 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8th, 2017, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 1824897.
The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might”, “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause the Company’s expectations to change.
Contact: William J. Peters Chief Financial Officer (909) 476-3416


Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 



